Notably, when the five post-operative CRC patients treated with a combination of bevacizumab with FOLFIRI were examined (Supplementary Fig. S1), they exhibited lower circulating VEGF-A levels during the 12 cycles of treatment. The gene discussed is VEGFA; the disease is colorectal carcinoma.